Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
暂无分享,去创建一个
Gerard N. Jager | R. Greil | M. Cazzola | B. Ehmer | D. Messinger | D. Bron | V. Silingardi | R. Cimino | U. Essers | A. Najman | M. Spriano | A. Grossi | A. van Hoof | G. Jäger | V. Battistel | G. Jager | L. Enller-Ziegler | A. Lemevel | Diethelrn Messinger | Renato Cirnino | Liana Enller-Ziegler | Ute Essers | Annick Lemevel | Albert Najrnan | Achiel van
[1] J. Spivak. Recombinant human erythropoietin and the anemia of cancer. , 1994, Blood.
[2] H. Samonigg,et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments] , 1994 .
[3] M. Goldberg,et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. , 1993, Blood.
[4] G. Fillet,et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production , 1992, British journal of haematology.
[5] S. Krantz,et al. Progress in understanding the pathogenesis of the anemia of chronic disease. , 1992, Blood.
[6] B. Klein,et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.
[7] M. Mittelman,et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. , 1992, Blood.
[8] M. Goldberg,et al. EFFECT OF INFLAMMATORY CYTOKINES ON HYPOXIA-INDUCED ERYTHROPOIETIN PRODUCTION , 1992 .
[9] M. Cazzola,et al. NEW TOOLS FOR CLINICAL EVALUATION OF ERYTHRON FUNCTION IN MAN , 1992, British journal of haematology.
[10] M. Ratain,et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Spivak,et al. Erythropoietin is both a mitogen and a survival factor. , 1991, Blood.
[12] M. Goldberg,et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. , 1990, Blood.
[13] H. Gisslinger,et al. Erythropoietin treatment of anemia associated with multiple myeloma. , 1990, The New England journal of medicine.
[14] R. Mertelsmann,et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Koury,et al. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.
[16] S. Tucker,et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Adamson,et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. , 1989, The New England journal of medicine.
[18] J. Adamson,et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.
[19] R. Weiss,et al. Neoplasia and the erythron. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Worsley. Testing for a Two-Phase Multiple Regression , 1983 .
[21] D. Siegmund,et al. Maximally Selected Chi Square Statistics , 1982 .
[22] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[23] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[24] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[25] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[26] H. Samonigg,et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. , 1994, Blood.
[27] M. Cazzola,et al. Guidelines for the use of recombinant human erythropoietin. , 1994, Haematologica.
[28] Berthold Lausen,et al. Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales , 1994 .
[29] J. Eschbach. Erythropoietin: the promise and the facts. , 1994, Kidney international. Supplement.
[30] J. Kugler,et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. , 1993, Journal of the National Cancer Institute.
[31] B. Barlogie,et al. Recombinant human erythropoietin and the anemia of multiple myeloma , 1993, Stem cells.
[32] D C Case,et al. Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.